Antiviral drugs for influenza for 2020-2021Article Published on 2020-11-022023-07-12 Journal: The Medical letter on drugs and therapeutics [Category] SARS, [키워드] adverse effects amantadine antiviral drugs baloxavir coronavirus dosage Drug interactions Efficacy FluMist Influenza influenza vaccine lactation neuraminidase inhibitors oseltamivir Peramivir Pregnancy Rapivab Relenza Rimantadine Safety Tamiflu Xofluza zanamivir
Nasal lavage containing Angiotensin-Converting Enzyme-2 agonist can prevent and reduce viral load in COVID-19Angiotensin-Converting Enzyme-2 agonist를 함유한 비강 세척은 COVID-19의 바이러스 부하를 예방하고 감소시킬 수 있습니다Article Published on 2020-11-012022-09-11 Journal: Medical Hypotheses [Category] SARS, 치료제, [키워드] ACE inhibitor ACE inhibitors angiotensin angiotensin converting enzyme angiotensin receptor blocker Angiotensin receptor blockers Angiotensin-converting enzyme angiotensin-converting enzyme-2 Anosmia ARBs binding can be used Chain Reaction changes in conditions COVID-19 COVID-19 negative Critical Diagnosis Dilution dosage Efficacy enzyme evaluated False negative False negative rate Formulation heart rate high risk high risk patients hypothese hypotheses include infect cells low blood pressure management medicated medication mode mucosa nasal Nasal lavage nasal mucosa nasal symptom olfactory Olfactory pathway Patient patients PCR penetrate polymerase chain polymerase chain reaction positive patients Potential Prevent raise receptor Receptor Blockers receptors reduce report reported SARS-CoV-2 SARSCoV-2 secondary to Side effect suspicion Symptom trials Vaccine Viral Viral load water [DOI] 10.1016/j.mehy.2020.110207 PMC 바로가기 [Article Type] Article
Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma AllianceOriginal Article Published on 2020-10-302022-10-28 Journal: Strahlentherapie Und Onkologie [Category] COVID-19, MERS, SARS, [키워드] affecting Alliance analyzed Care coronavirus COVID COVID-19 pandemic criteria Critical dosage expert feasible group health systems hematology indication indolent Infection leukemia lymphoma Multiple myeloma oncology pandemic Patient Patient care patient triage question questionnaire Radiation radiation therapy radiation treatment receive recommendation reduced regimen resource Result SARS-CoV-2 Stage supplementary material syndrome Treatment underlying disease vena were assessed [DOI] 10.1007/s00066-020-01705-w PMC 바로가기 [Article Type] Original Article
Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMOOriginal Article Published on 2020-10-192022-10-29 Journal: TH Open: Companion Journal to Thrombosis and Haemostasis [Category] COVID-19, [키워드] activated acute phase reactants Analysis anti-Xa aPTT association C-reactive protein Concentration coronavirus disease correlated correlation COVID-19 COVID-19 patient CRRT dosage ECMO explained extracorporeal membrane oxygenation ferritin fibrinogen FVIII heparin Heparin resistance heparin therapeutic range Linear regression mandatory material monitoring objective optical patients Prevent renal replacement therapy Result therapeutic Thrombocytes Treatment variable were measured were used [DOI] 10.1055/s-0040-1719083 PMC 바로가기 [Article Type] Original Article
From Standard to Escalated Anticoagulant Prophylaxis in Fractured Older Adults With SARS-CoV-2 Undergoing Accelerated Orthopedic SurgeryMedicine Published on 2020-10-152022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] Anticoagulant Anticoagulants Antithrombotic bases cardiovascular complication complications COVID-19 COVID-19 drug treatment daily dose death deaths dosage doubling Efficacy faster femoral fractures High dose high risk highest hospital incidence increased survival infected patient Injury Italian Italy knowledge lombardy Low-molecular-weight heparin mandatory metabolic derangement nine Older orthopedic pandemic pathophysiology Patient patients pharmacological treatment Prevalence Prophylaxis protocol reduction in SARS-CoV-2 SARS-COV-2 infection Seven Spread Standard statistically significant subsequent surgeon surgery surgical Symptom the disease trauma treated Treatment virus [DOI] 10.3389/fmed.2020.566770 PMC 바로가기 [Article Type] Medicine
Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-AnalysisPharmacology Published on 2020-10-142022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] 2019 coronavirus disease 95% confidence interval adverse event adverse events AEs Affect Analysis Antiviral assessment Chloroquine control patients Controlled COVID-19 COVID-19 patient COVID-19 patients dosage drug estimate evaluated exhibited four group HCQ Hydroxychloroquine immunomodulatory inclusion criteria involved limit measure medication medications Meta-analysis Mild neurologic OSF other diseases outcomes participant patients performed Placebo random-effect Randomized controlled trial RCT RCTs Registered Registration Result review risk Risk of bias Safety safety profile safety profiles searched significantly higher subgroup analysis suggested treat Treatment Trial unlikely were used [DOI] 10.3389/fphar.2020.562777 PMC 바로가기 [Article Type] Pharmacology
Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort studyOriginal Article Published on 2020-10-142022-10-31 Journal: Clinical & Translational Immunology [Category] COVID-19, [키워드] administration Analysis carried China clinical Clinical efficacy clinical study Cohort coronavirus disease Coronavirus disease 2019 COVID‐19 COVID‐19 patient COVID‐19 Critical decrease disease dosage early stage Efficacy enrolled Evidence exhibited High dose ill patient Immunoglobulin IMPROVE Inflammatory response information Intravenous immunoglobulin IVIG Mortality multicenter objective organ function outbreak Patient patient selection patients per day Primary outcome Prognosis provide reduce reduction in Result retrospective cohort study SARS‐CoV‐2 infection SARS‐CoV‐2 secondary outcome significantly the disease therapy treat Treatment [DOI] 10.1002/cti2.1192 PMC 바로가기 [Article Type] Original Article
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial입원한 COVID-19 환자의 결과 개선에 대한 파모티딘의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-10-132022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] Alanine Alanine transaminase alcoholism All participant All participants allergies allergy allocation approved ARMS aspartate Aspartate transaminase assigned assumption Bandar Abba Bandar Abbas baseline Blinding block randomization blood count Care Chronic kidney disease clearance clinical clinical trial clinical trials code Committee company comparator Comparator group complete blood count concealed control group control groups COVID-19 COVID-19 patient COVID-19 patients creatinine creatinine clearance criteria Dasatinib dialysis discharge dissemination dosage drug therapy electrocardiogram element eligibility criteria End-stage renal disease ethics committee Evidence evidence of excluded expected Famotidine G6PD Glucose Glucose 6 phosphate grouping groups Hepatitis hepatitis C Hospitalized Immunocompromised Immunocompromised patients Infection Intervention Kidney disease Lactate lactate dehydrogenase lead limit Liver disease Local lung infiltration maximum Medical Science Medical Sciences moderate need for dialysis Neratinib normal limit number objective online tool oral contraceptives outcome outcome assessor outcome assessors oxygen oxygen saturation Ozanimod participant Patient patients patients with COVID-19 Pazopanib PCR test pharmaceutical Pharmaceutical Company phosphate Placebo placebo-controlled porphyria positive Pregnancy protocol psoriasis random randomisation randomised randomised controlled trial randomized clinical trial Randomly randomly divided receive recruitment Registered registry renal renal disease renal failure reported Research question researcher respiration rate responsible Rilpivirine Sample size sample size calculation sequence sequence information single-blind Siponimod Standard study drug Study protocol subject submitted technology temperature the ethics committee therapy title Tizanidine transaminase Treatment treatment group Treatment protocol treatment protocols Trial registration two group two groups university Version website were measured written consent [DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter
Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling AnalysisResearch Article Published on 2020-10-082022-10-28 Journal: PLoS Computational Biology [Category] COVID-19, MERS, SARS, [키워드] ACE2 ACE2 protein acute inflammatory response Angiotensin II angiotensin-converting enzyme inhibitor approach ARB binding blocker cardiovascular disease cardiovascular diseases Cell cell entry cell membrane chronic inflammation Chronic kidney disease coronavirus COVID-19 COVID-19 pandemic diabete diabetes disease disease severity dosage drug Effects enzyme epidemiological data epithelial cell Evidence exacerbated Factors heart failure help host cell host cells host’s immune response hypertension implication increase in induce Infection Inflammation inhibitor Invasion lack lethal disease Lungs mathematical medication medications Model modeling Mortality pandemic Pandemics pathogenesis of COVID-19 Patient physician predict RAS receptor renin-angiotensin system risk SARS- CoV-2 SARS-CoV SARS-CoV-2 severe COVID-19 subsequent suggested the spike protein therapy tissue damage tissues treated Treatment virus while [DOI] 10.1371/journal.pcbi.1008235 PMC 바로가기 [Article Type] Research Article
Comparative docking studies to understand the binding affinity of nicotine with soluble ACE2 (sACE2)-SARS-CoV-2 complex over sACE2Regular Article Published on 2020-10-082022-10-29 Journal: Toxicology Reports [Category] COVID-19, [키워드] absence Abstract ACE2 Amino acid Angiotensin-converting enzyme angiotensin-converting enzyme 2 bind binding binding affinity clinical trial Comparative complex conserved Contact COVID19 docked docking study dosage Infection inhibitory Interaction Lower neuronal Neuronal nicotinic acetylcholine receptor Nicotine patients Protein protein complex RBD domain receptor recorded reduced reducing required sACE2 sACE2 protein sACE2-INS1 complex SARS-CoV-2 SARS-CoV-2 protein sequence identity Smokers soluble ACE2 the binding affinity the healthy the SARS-CoV-2 therapeutic efficacy turn virulence [DOI] 10.1016/j.toxrep.2020.10.002 PMC 바로가기 [Article Type] Regular Article